SpotitEarly
Healthcare technology
AI-enabled, breath-based multi-cancer early detection
Series A (announced as open in May 2025); the comp
SpotitEarly is a health-technology company developing a non-invasive, breath-based cancer pre-screening test. Its platform combines analysis of volatile organic compounds in breath samples, trained dogs’ scent detection, and AI to identify signals associated with multiple cancers. The company launched in the U.S. in 2025 and has described clinical research and validation as ongoing. Its tests are under development and have not been approved by the U.S. Food and Drug Administration, so they should not be represented as established diagnostic or screening products.
Company Details
- Website
- spotitearly.com
- Headquarters
- Englewood, New Jersey, United States
- Founded
- 2020
- Funding
- $20.3 million publicly reported as raised by May 2025; the company’s current public-offering website
Subscriber Intelligence
- • Deal signal alerts for this company
- • Sentiment & risk scoring
- • Competitive framework analysis
- • Regulatory event monitoring